Cargando…

Time to Treatment Prediction in Chronic Lymphocytic Leukemia Based on New Transcriptional Patterns

Chronic lymphocytic leukemia (CLL) is the most frequent lymphoproliferative syndrome in western countries. CLL evolution is frequently indolent, and treatment is mostly reserved for those patients with signs or symptoms of disease progression. In this work, we used RNA sequencing data from the Inter...

Descripción completa

Detalles Bibliográficos
Autores principales: Mosquera Orgueira, Adrián, Antelo Rodríguez, Beatriz, Alonso Vence, Natalia, Bendaña López, Ángeles, Díaz Arias, José Ángel, Díaz Varela, Nicolás, González Pérez, Marta Sonia, Pérez Encinas, Manuel Mateo, Bello López, José Luis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6384245/
https://www.ncbi.nlm.nih.gov/pubmed/30828568
http://dx.doi.org/10.3389/fonc.2019.00079
Descripción
Sumario:Chronic lymphocytic leukemia (CLL) is the most frequent lymphoproliferative syndrome in western countries. CLL evolution is frequently indolent, and treatment is mostly reserved for those patients with signs or symptoms of disease progression. In this work, we used RNA sequencing data from the International Cancer Genome Consortium CLL cohort to determine new gene expression patterns that correlate with clinical evolution.We determined that a 290-gene expression signature, in addition to immunoglobulin heavy chain variable region (IGHV) mutation status, stratifies patients into four groups with notably different time to first treatment. This finding was confirmed in an independent cohort. Similarly, we present a machine learning algorithm that predicts the need for treatment within the first 5 years following diagnosis using expression data from 2,198 genes. This predictor achieved 90% precision and 89% accuracy when classifying independent CLL cases. Our findings indicate that CLL progression risk largely correlates with particular transcriptomic patterns and paves the way for the identification of high-risk patients who might benefit from prompt therapy following diagnosis.